Note: This document is a translation of a part of the Japanese original for reference purposes only. In the event of any discrepancy
between this translation and the Japanese original, the original shall prevail.

Securities code: 2309
November 30, 2023
Start date of measures for electronic provision: November 22, 2023
To our shareholders,Kazuo Nakamura
Chairman & CEO
CMIC HOLDINGS Co., Ltd.
1-1-1 Shibaura, Minato-ku, Tokyo

Notice of the Convocation of the 39th Ordinary General Meeting of
Shareholders
We are pleased to announce the 39th Ordinary General Meeting of Shareholders of CMIC HOLDINGS Co.,
Ltd. (the “Company”), which will be held as described below.
When convening this general meeting of shareholders, the Company takes measures for providing
information that constitutes the content of reference documents for the general meeting of shareholders, etc.
(items for which measures for providing information in electronic format are to be taken) in electronic format,
and posts this information on the Company’s website. Please access the following websites to review the
information.
The Company’s website:
https://en.cmicgroup.com/investor-relations-overview/shareholders-meeting/In addition to posting items subject to measures for electronic provision on the Company’s website, theCompany also posts this information on each website. Please review this information on the following
websites.
TSE website:
https://www2.jpx.co.jp/tseHpFront/JJK020010Action.do?Show=Show(Access the TSE website shown above, enter “CMIC HOLDINGS” in “Issue name (company name)” or
the Company’s securities code “2309” in “Code,” and click “Search.” Then, click “Basic information”
and select “Documents for public inspection/PR information.” Under “Filed information available forpublic inspection,” click “Click here for access” under “[Notice of General Shareholders Meeting/Informational Materials for a General Shareholders Meeting].”)If you are unable to attend the meeting in person, you may exercise your voting rights via the internet or inwriting (by postal mail). Please review the “Reference Documents for the General Meeting of Shareholders”
and exercise your voting rights by 5:30 p.m. on Thursday, December 14, 2023.

11. Date and time:
2. Place:

Friday, December 15, 2023 at 10:00 a.m.
Main Hall, Hamamatsucho Convention Hall (Nippon Life Hamamatsucho Crea
Tower 5F)
2-3-1 Hamamatsucho, Minato-ku, Tokyo

3. Agenda:
Matters to be reported:
1. Report on the business report, the consolidated financial statements for the 39th fiscal year (fromOctober 1, 2022 to September 30, 2023) and the results of the audit of the consolidated financial
statements by the financial auditor and the Audit and Supervisory Board
2. Report on the non-consolidated financial statements for the 39th fiscal year (from October 1, 2022
to September 30, 2023)
Matters to be resolved:
Proposal 1: Election of Nine (9) Corporate Directors
Proposal 2: Election of One (1) Audit and Supervisory Board Member
4. Matters decided upon convocation (Information on exercise of voting rights)(1) If you exercise your voting rights in writing (by postal mail) and indicate neither approval nor
disapproval of the proposals, the Company will deem that you indicated your approval of suchproposals.
(2) If you exercise your voting rights more than once via the internet, the Company will only deem
your last exercise of voting rights as valid.
(3) If you exercise your voting rights in duplicate both via the internet and in writing (by postal mail),the Company will only deem your exercise of voting rights via the internet as valid, regardless ofthe date and time of arrival.
(4) If you exercise your voting rights by proxy, you may designate one other shareholder holding
voting rights in the Company to attend the meeting. Please note, however, that it is necessary tosubmit a document proving the authority of the proxy.
◎ For those attending the meeting on the day, please submit the voting form at the reception desk.
◎ If revisions to the items subject to measures for electronic provision arise, a notice of the revisions andthe details of the items before and after the revisions will be posted on the Company’s aforementioned
website and each website.
◎ Paper-based documents stating items subject to measures for electronic provision are sent toshareholders who have requested the delivery of paper-based documents, however those documents do
not include the following items in accordance with the provisions of laws and regulations and Article
14 of the Company’s Articles of Incorporation.
i) Notes to the Consolidated Financial Statementsii) Notes to the Non-consolidated Financial Statements
Therefore, the consolidated financial statements and the non-consolidated financial statements stated in
the said documents are part of the documents that were audited by the financial auditor in preparing theaccounting audit report, and by Audit and Supervisory Board Members in preparing the audit report.

2

Reference Documents for the General Meeting of Shareholders
Proposal 1:

Election of Nine (9) Corporate Directors

At the conclusion of this Ordinary General Meeting of Shareholders, the terms of office of all ten (10)Corporate Directors will expire. In that regard, in order to change the management structure and expedite
decision-making, the Company proposes to elect a total of nine (9) Corporate Directors (of which, four (4)are to be External Corporate Directors), thereby decreasing the number of Corporate Directors by one (1).
The candidates for Corporate Director are as follows:
Candidate
No.

Name

Current positionin the Company
Representative Director, Chairman
and CEO

Candidate attributes
Reelection

1

Kazuo Nakamura

2

Keiko Oishi

Representative Director, President
and COO

Reelection

3

Makoto Matsukawa

Corporate Director and Vice President

Reelection

4

Wataru Mochizuki

Corporate Director and CFO

Reelection

5

Akihisa Mitake

Corporate Director

Reelection

6

Masaru Iwasaki

External Corporate Director

Reelection

External

Independent

7

Takeshi Karasawa

External Corporate Director

Reelection

External

Independent

8

Gregg Lindstrom Mayer

External Corporate Director

Reelection

External

Independent

9

Masaru Ota

External Corporate Director

Reelection

External

Independent

Note: Ms. Keiko Oishi’s name on the family register is Keiko Nakamura.

3

Candidate No.

1

Reelection
Number of the Company’s shares owned: 565,620 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1969 Joined Sankyo Co., Ltd. (currently Daiichi Sankyo Co., Ltd.)Mar. 1992 Representative Director and President, the Company

Kazuo Nakamura(December 17, 1946)

Oct. 2003

Representative Director, Chairman and President CEO, the Company

Dec. 2013

Representative Director, Chairman and President CEO, the Company (change
of Japanese title only)

Apr. 2018

Representative Director, Chairman and CEO, the Company

Apr. 2021

Representative Director, Chairman and CEO, the Company (to present)(change of Japanese title only)

Oct. 2021

Division Director of Healthcare Revolution Business, the Company

Oct. 2022

In charge of Healthcare Revolution Business, the Company

Oct. 2023

Division Director of Drug Discovery Support Business, the Company (topresent)[Reasons for nomination as candidate for Corporate Director]
After working in research and development at a large pharmaceutical corporation, Mr.
Kazuo Nakamura founded the Company. He possesses outstanding abilities in executive
management, which he has used to steer the Company as a leading company. As theCompany expects him to continue to perform a decision-making and supervisory role inmanagement, it again nominated him as a candidate for Corporate Director.

4Candidate No.

2

Reelection
Number of the Company’s shares owned: 154,000 shares
Attendance to meetings of the Board of Directors: 11/12 (92%)[Career summary, and position and responsibility in the Company]
Apr. 1982 Joined Nikkei/McGraw-Hill Inc. (currently Nikkei Business Publications, Inc.)

Keiko Oishi(January 3, 1957)

Oct. 1989

Joined Genentech, Inc.

Jan. 1996

Joined the Company

July 2000

Corporate Director, the Company

Oct. 2004

Corporate Director and Vice President, the Company

Dec. 2010

Representative Director, the Company

Apr. 2011

Representative Director, Corporate Officer, in charge of International Business,
the Company

Dec. 2013

Representative Director, Executive Vice President, Division Head ofInternational Business Development Div., the Company

Oct. 2016

Representative Director, Executive Vice President, CEO of CRO Business,
Division Head of International Business Management Div., the Company

Apr. 2018

Representative Director, President and COO, Supervisory Manager of Business
Development & Marketing, the Company

Apr. 2021

Representative Director, President and COO, CHO, Supervisory Manager ofBusiness Development & Marketing, the Company(Name on the family register:Oct. 2021
Keiko Nakamura)
Oct. 2022

Representative Director, President and COO, Division Director of CRO
Business, the Company
Representative Director, President and COO, Division Director of CRO
Business, the Company (to present)

Significant concurrent positions outside the Company:
Representative Director, Chairperson, CMIC Co., Ltd.
[Reasons for nomination as candidate for Corporate Director]
With extensive experience at international corporations, Ms. Keiko Oishi has been amember of the Company’s senior management since the Company was founded, and she
possesses outstanding abilities in executive management. During her time as President of
the Company, her efforts toward “globalization” and “training of personnel for
globalization” particularly stand out. As the Company expects her to continue to perform adecision-making and supervisory role in management, it again nominated her as a candidate
for Corporate Director.

5Candidate No.

3

Reelection
Number of the Company’s shares owned: 3,640 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1984 Joined Akiyama Inc. (currently SUZUKEN CO., LTD.)

Makoto Matsukawa(March 30, 1960)

Oct. 1989

Joined Baxter Limited

June 1999

Joined Starbucks Coffee Japan, Ltd.

Apr. 2007

Joined Quintiles Transnational Japan K.K. (currently IQVIA Services Japan
K.K.)

Jan. 2012

Joined the Company, Corporate Officer, in charge of Corporate Planning/IPD

Dec. 2012

Corporate Director, Corporate Officer and IPD Company President, theCompany

May 2015

Senior Executive Officer, in charge of Business Development, the Company

Oct. 2016

Senior Executive Officer, in charge of Business Development, CEO of CDMO
Business, the Company

Dec. 2016

Corporate Director, the Company

Apr. 2018

Corporate Director and Executive Vice President, Supervisory Manager of
CDMO, Supervisory Manager of CSO, the Company

Nov. 2018 Corporate Director and Executive Vice President, Supervisory Manager of
CDMO, the Company
Apr. 2021

Corporate Director and CVO, Division Director of CDMO Business, theCompany

Oct. 2022

Corporate Director and Vice President, in charge of Corporate Development,
the Company (to present)

Significant concurrent positions outside the Company:
Representative Director & CEO, CMIC CMO Co., Ltd.
[Reasons for nomination as candidate for Corporate Director]
Having started up businesses in various industry sectors including not only thepharmaceutical sector, but also large-player service sector, Mr. Makoto Matsukawa
possesses management experience and plays an instrumental role in globalization andstrategic business development within the Company. As the Company expects him tocontinue to perform a decision-making and supervisory role in management, it again
nominated him as a candidate for Corporate Director.

6

Candidate No.

4

Reelection
Number of the Company’s shares owned: 5,500 shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1985 Joined Nippon Oil & Fats Co., Ltd. (currently NOF CORPORATION)
Jan. 1997

Joined Allied Telesis Holdings K.K.

Aug. 2005 Joined the Company
Oct. 2010
Dec. 2010

Corporate Director, the Company

Oct. 2012

Corporate Director, Corporate Officer and CFO, in charge of Internal
Control/Information Disclosure, the Company

Oct. 2013

Corporate Director, Senior Corporate Officer and CFO, in charge of Financeand Legal Affairs Department/Internal Control/Information Disclosure, theCompany

May 2015

Corporate Director, Executive Vice President and CFO, in charge of Internal
Control/Information Disclosure, the Company

Apr. 2018

Corporate Director, Executive Vice President and CFO, Supervisory Manager
of Administration and Support Unit, the Company

Apr. 2021

Corporate Director and CFO, responsible for Group Information
Disclosure/Internal Control, the Company (to present)

Wataru Mochizuki(December 10, 1961)

Corporate Officer, in charge of Internal Control/Information
Disclosure/Finance and Accounting, the Company[Reasons for nomination as candidate for Corporate Director]
With extensive knowledge and experience in administrative departments, Mr. Wataru
Mochizuki possesses outstanding abilities in executive management. As the Company
expects him to continue to perform a decision-making and supervisory role in management,
it again nominated him as a candidate for Corporate Director.

7

Candidate No.

5

Reelection
Number of the Company’s shares owned: 26,540 shares
Attendance to meetings of the Board of Directors: 10/10 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1986 Joined Kotai Kasei Co., Ltd. (currently TAIHO PHARMACEUTICAL CO.,LTD.)
July 1993

Joined the Company

Apr. 2008

Director and Vice President, CMIC Korea Co., Ltd.

Nov. 2009 Corporate Officer, Division Head of Business Development Div., the Company
Oct. 2014

President, CMIC Bioresearch Center Co., Ltd. (currently CMIC Pharma
Science Co., Ltd.)May 2015

Senior Corporate Officer, the Company

Oct. 2016

President, Site Support Institute Co., Ltd. (currently CMIC HealthCare
Institute Co., Ltd.)

Dec. 2017 Director and Senior Executive Officer, the Company

Akihisa Mitake(October 24, 1963)

Oct. 2022

Division Director of CRO Business (in charge of Clinical CRO Business) (topresent)
President, CMIC Co., Ltd. (to present)

Dec. 2022 Corporate Director, the Company (to present)
Significant concurrent positions outside the Company:
President, CMIC Co., Ltd.
[Reasons for nomination as candidate for Corporate Director]
After accumulating development experience at a pharmaceutical corporation, Mr. Akihisa
Mitake has engaged in numerous positions at the Company over many years since its initialfounding period. He served in important positions at the Company’s subsidiaries since2008, contributing to the continual growth of businesses in his responsibility. As theCompany expects him to perform a decision-making and supervisory role in management
based on his extensive experience and achievements in the Company’s business, it again
nominated him as a candidate for Corporate Director.

8

Candidate No.

6

Reelection External Independent
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: 11/12 (92%)[Career summary, and position and responsibility in the Company]
Dec. 1973 Joined Department of Surgery II, The University of Tokyo Hospital
Apr. 1983

Joined Department of Surgery II, Faculty of Medicine, University of Yamanashi

Apr. 1993

Joined Hoechst Japan Co., Ltd. (currently Sanofi K.K.)

Jan. 2005

Joined GlaxoSmithKline K.K.

Sept. 2011 Specially Appointed Professor, Department of Clinical Research, Faculty of
Medicine, University of Yamanashi
Sept. 2014 Specially Appointed Professor, Department of Advanced Biomedical Research,
Faculty of Medicine, University of Yamanashi (to present)
Apr. 2015

Vice President, University of Yamanashi (to present)

Dec. 2016 External Corporate Director, the Company (to present)

Masaru Iwasaki(May 3, 1947)

Significant concurrent positions outside the Company:
Vice President, University of Yamanashi
Program Director, Japan Agency for Medical Research and Development
Visiting Professor, Juntendo University School of Medicine[Reasons for nomination as candidate for External Corporate Director and summaryof expected role]
After working as a clinician in the oncology area, Mr. Masaru Iwasaki possesses experienceand achievements from serving in important positions for large pharmaceutical corporations
in areas including product strategy planning and product development. He has performed an
important role in the Company’s management as an External Corporate Director from atechnical perspective of pharmaceuticals and healthcare since December 2016. As theCompany expects him to continue fulfilling the role of advising and supervising its overallmanagement, it again nominated him as a candidate for External Corporate Director.

9Candidate No.

7

Reelection External Independent
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: 12/12 (100%)[Career summary, and position and responsibility in the Company]
Apr. 1980 Joined Ministry of Health and Welfare (currently Ministry of Health, Labourand Welfare)
July 2000

Director, Public Relations Office, General Coordination Division, Minister’s
Secretariat, Ministry of Health and Welfare

July 2004

Director, National Health Insurance Division and Director, General Affairs
Division, Health Insurance Bureau, Ministry of Health, Labour and Welfare

July 2009

Deputy Director-General (in charge of Medical Insurance, Health Policy, HealthCare and Long-term Care Integration), Ministry of Health, Labour and Welfare

Sept. 2012 Director-General for Policy Planning and Evaluation (in charge of Social
Security), Ministry of Health, Labour and Welfare
July 2014

Director General, Health Insurance Bureau, Ministry of Health, Labour andWelfareJune 2016 Director-General for Regional Revitalization, Headquarters for Overcoming
Population Decline and Vitalizing Local Economy in Japan, Cabinet Secretariat
Aug. 2016 Retired from Cabinet Secretariat

Takeshi Karasawa

Dec. 2018 External Corporate Director, the Company (to present)(August 29, 1956)
Significant concurrent positions outside the Company:
Director, Social Welfare Corporation Sun Vision
Outside Director, Value HR Co., Ltd.
[Reasons for nomination as candidate for External Corporate Director and summaryof expected role]
Mr. Takeshi Karasawa possesses extensive achievements and highly specialized knowledgeof healthcare and nursing care related policies and the social security system in generalfrom his experience in government administration. He has performed an important role in
the Company’s management as an External Corporate Director from an independent
perspective since December 2018. In addition, as the chairperson of the Nomination andRemuneration Committee, he proactively expresses his opinions regarding selection ofcandidates for Directors, Officers, and Audit & Supervisory Board Members of theCompany and decisions on their remuneration, etc., and contributes from an objective andneutral standpoint. As the Company expects him to continue providing us with practicaladvice on the Company’s business strategy and promotion, it again nominated him as a
candidate for External Corporate Director.

10Candidate No.

8

Reelection External Independent
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: 11/12 (92%)[Career summary, and position and responsibility in the Company]
June 1981 Co-Founder and Partner, BERKELEY ANTIBODY COMPANY, INC.
Apr. 1983

President and Director, BERKELEY ANTIBODY COMPANY, INC.

Jan. 1986

Joined VIVIGEN, INC.

Jan. 1988

President, VIVIGEN, INC.

Mar. 1993

Joined MCKINSEY & COMPANY

June 1994

Director, UNM RAINFOREST INNOVATIONS (to present)

Feb. 1995

President & CEO, GREGG L. MAYER & COMPANY, INC. (to present)

Sept. 1996 Director, KAISER PERMANENTE INTERNATIONAL

Gregg Lindstrom
Mayer(August 15, 1958)

Jan. 2005

Director, DISEASE MANAGEMENT ASSOCIATION OF JAPAN

Dec. 2021

External Corporate Director, the Company (to present)

Significant concurrent positions outside the Company:
Co-Chair, Population Health Research Committee ASIA PACIFIC SOCIETY FORHEALTH SUPPORT SCIENCES[Reasons for nomination as candidate for External Corporate Director and summaryof expected role]
Mr. Gregg Lindstrom Mayer possesses extensive experience and expertise in disease
management, business development, etc. in the pharmaceutical, medical device,biotechnology and healthcare industries. He is also familiar with Japan’s healthcare
administration and the Company expects that he will be able to provide us with practicaladvice on the Company’s global strategy and promotion. The Company therefore
nominated him as a candidate for External Corporate Director.

11

Candidate No.

9

Reelection External Independent
Number of the Company’s shares owned: – shares
Attendance to meetings of the Board of Directors: 8/10 (80%)[Career summary, and position and responsibility in the Company]
Oct. 1991 Joined Aoyama Audit Corporation (currently PricewaterhouseCoopers Aarata
LLC)

Masaru Ota(June 8, 1966)

Mar. 1997

Joined PwC Consulting Co., Ltd. (currently IBM Japan Ltd)

Oct. 1999

Joined ChuoAoyama Audit Corporation

Mar. 2001

Joined Sanwa Capital Finance Ltd. (currently Mitsubishi UFJ Capital Co.,Ltd.)

Dec. 2002

Joined Phoenix Capital Co., Ltd.

Mar. 2003

Director, Phoenix Capital Co., Ltd.

Apr. 2006

Representative Director, Ascent Partners (to present)

June 2015

Outside Corporate Auditor, MORITA HOLDINGS CORPORATION (topresent)

June 2017

Outside Audit & Supervisory Board Member, Wealth Management, Inc.

Dec. 2019

External Audit and Supervisory Board Member, the Company

June 2022

Audit and Supervisory Committee Member and Outside Board Member,
Wealth Management, Inc. (to present)

Dec. 2022

External Corporate Director, the Company (to present)

Significant concurrent positions outside the Company:
Representative Director, Ascent Partners
Outside Corporate Auditor, MORITA HOLDINGS CORPORATION
Audit and Supervisory Committee Member and Outside Board Member, WealthManagement, Inc.
[Reasons for nomination as candidate for External Corporate Director and summaryof expected role]
Mr. Masaru Ota possesses extensive knowledge and experience as a certified public
accountant and consultant. In addition, as the member of the Nomination and Remuneration
Committee, he proactively expresses his opinions regarding selection of candidates for
Directors, Officers, and Audit & Supervisory Board Members of the Company anddecisions on their remuneration, etc., and contributes from an objective and neutral
standpoint. As the Company expects him to provide us with practical advice on the
Company’s business strategy and promotion using his experience and knowledge, it again
nominated him as a candidate for External Corporate Director.
Notes:

1. There is no special interest between any of the candidates and the Company.
2. Mr. Masaru Iwasaki, Mr. Takeshi Karasawa, Mr. Gregg Lindstrom Mayer and Mr. Masaru Ota are candidates forExternal Corporate Director.
3. Mr. Masaru Iwasaki is currently an External Corporate Director of the Company, and at the conclusion of thismeeting, his tenure as External Corporate Director will have been seven (7) years.
4. Mr. Takeshi Karasawa is currently an External Corporate Director of the Company, and at the conclusion of thismeeting, his tenure as External Corporate Director will have been five (5) years.
5. Mr. Gregg Lindstrom Mayer is currently an External Corporate Director of the Company, and at the conclusion ofthis meeting, his tenure as External Corporate Director will have been two (2) years.
6. Mr. Masaru Ota is currently an External Corporate Director of the Company, and at the conclusion of this meeting,his tenure as External Corporate Director will have been one (1) year.
7. The Company has entered into an agreement, in accordance with Article 427, paragraph (1) of the Companies Act,with Mr. Masaru Iwasaki, Mr. Takeshi Karasawa, Mr. Gregg Lindstrom Mayer and Mr. Masaru Ota to limit their
liability to compensate damages under Article 423, paragraph (1) of the same Act. The maximum amount ofliability for damages under this agreement is the minimum liability amount provided for by the laws andregulations. If their reelection is approved, the Company plans to continue the agreement with each one of them.
8. The Company has submitted notification to the Tokyo Stock Exchange that Mr. Masaru Iwasaki, Mr. Takeshi
Karasawa, Mr. Gregg Lindstrom Mayer and Mr. Masaru Ota have been appointed as independent officers asprovided for by the aforementioned exchange. Should their reelection be approved, the Company intends to submit
notification that they have been appointed as independent officers.

129. The Company has entered into a directors and officers liability insurance policy as provided for in Article 430-3,
paragraph (1) of the Companies Act with an insurance company. In the event that an insured is claimed for damagesby a shareholder or a third party in connection with the performance of their duties, the policy will cover losses
including indemnification for such damages and litigation expenses. If this proposal is approved and adopted, andeach of them is appointed as a Corporate Director of the Company, they will be included as insureds of theinsurance policy. In addition, the Company plans to renew the policy with the same details at the next renewal.

13

Proposal 2:

Election of One (1) Audit and Supervisory Board Member

At the conclusion of this Ordinary General Meeting of Shareholders, the term of office of Audit andSupervisory Board Member Kei Hata will expire. In that regard, the Company proposes the election of one(1) Audit and Supervisory Board Member. The consent of the Audit and Supervisory Board has been obtained
for this proposal.
The candidate for Audit and Supervisory Board Member is as follows:
Reelection External Independent
Number of the Company’s shares owned: – shares
Attendance to meetings of the Audit and Supervisory Board: 11/12 (92%)[Career summary and position in the Company]
Oct. 1981 Passed the national bar examination
Apr. 1984

Registered as attorney at law
Joined Kazama & Co. Law Offices (currently Hata & Co. Law Offices) (topresent)

Dec. 2015

External Audit and Supervisory Board Member, the Company (to present)

Kei Hata

Significant concurrent positions outside the Company:(May 23, 1953)

Representative, Hata & Co. Law Offices[Reasons for nomination as candidate for External Audit and Supervisory Board
Member]
The Company has again nominated Mr. Kei Hata as a candidate for External Audit andSupervisory Board Member in the expectation that he will continue to fulfill the role ofsupervision in the Company based on his extensive experience and insight gained from longyears of service as an attorney.

Notes:

1. There is no special interest between the candidate and the Company.
2. Mr. Kei Hata is a candidate for External Audit and Supervisory Board Member.
3. Mr. Kei Hata is currently an External Audit and Supervisory Board Member of the Company, and at the conclusionof this meeting, his tenure as External Audit and Supervisory Board Member will have been four (4) years.
4. The Company has entered into an agreement, in accordance with Article 427, paragraph (1) of the Companies Act,with Mr. Kei Hata to limit his liability to compensate damages under Article 423, paragraph (1) of the same Act.
The maximum amount of liability for damages under this agreement is the minimum liability amount provided forby the laws and regulations. If his reelection is approved, the Company plans to continue the agreement with him.
5. The Company has submitted notification to the Tokyo Stock Exchange that Mr. Kei Hata has been appointed as anindependent officer as provided for by the aforementioned exchange. Should his reelection be approved, theCompany intends to submit notification for his status to remain as independent officer.
6. The Company has entered into a directors and officers liability insurance policy as provided for in Article 430-3,
paragraph (1) of the Companies Act with an insurance company. In the event that an insured is claimed for damagesby a shareholder or a third party in connection with the performance of their duties, the policy will cover losses
including indemnification for such damages and litigation expenses. If this proposal is approved and adopted, andhe is appointed as an Audit and Supervisory Board Member of the Company, he will be included as insureds ofthe insurance policy. In addition, the Company plans to renew the policy with the same details at the next renewal.

14

<<Reference>>
Skill Matrix of Corporate Directors and Audit and Supervisory Board Members(In the event that each candidate for Corporate Director and Audit and Supervisory Board Member is elected)
Name

Finance/
Accounting

Legal affairs/
Riskmanagement

Businessknowledge●●

Globalbusiness

Corporate Directors

Kazuo Nakamura●

Keiko Oishi

●

●

●

Makoto Matsukawa

●

●

●

Wataru Mochizuki●

Akihisa Mitake

●

●

●

●

●

●

●

●

●

Masaru Iwasaki

Audit andSupervisory
Board
Members
Note:

Corporate
management

Takeshi Karasawa●

Gregg Lindstrom Mayer●

Masaru Ota

●

●

●
●

●

●

Takanori Tobe●

Kei Hata●

Hidetoshi Watanabe●●

Eiko Hakoda

●

●

●

●

The above list indicates up to three items that are particularly expected of each candidate, and does not exhaustively
describe all the knowledge and experience possessed by each candidate.

15